ERBB2 and cancer: Immunotherapy targeting the extracellulardomain (EDC) of HER2has been extensively developed as a specific approach to cancer research.Additionally, clinical therapies utilize specific antibodies or theirfragments directly conjugated to anticancer drugs to deliver themto HER2-positive tumor cells.−, , , ,